BioNTech’s CEO Ugur Sahin has said that he is confident that its current coronavirus vaccine will work effectively against the new variant in the virus, traced to the UK. He also believed that further studies were required.
On Tuesday, the chief executive said that “We don’t know at the moment if our vaccine is also able to provide protection against this new variant.” The new variant has the same proteins, as much as 99% similar, as the previous ones and hence the vaccine maker has “scientific confidence” in its vaccine.
The company is conducting additional studies to confirm the efficacy of its vaccine.
He added, “The likelihood that our vaccine works is relatively high…” He also said that in a worst-case scenario that “we could be able to provide a new vaccine technically within six weeks.”
More than 45 countries worldwide have authorized the use of the vaccine jointly developed by Pharma giant Pfizer and German pharmaceutical company BioNTech. The vaccine began its rollout in the U.S. and the UK. European Union nations are planning to begin vaccinations on December 27, 2020.
Moderna, another pharmaceutical company who has developed a different, effective vaccine, is also testing it on the new UK variant, a strain that has a faster rate of transmission.
This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.